From simulation to immunization: efficient non-viral delivery of HIV-1 Nefmut-Tat DNA construct using CM18-TAT11 cell penetrating peptide.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- From simulation to immunization: efficient non-viral delivery of HIV-1 Nefmut-Tat DNA construct using CM18-TAT11 cell penetrating peptide.
- Published In:
- International journal of pharmaceutics, 686, 126334 (2025)
- Authors:
- Gheydi, Mostafa, Bolhassani, Azam(2), Negahdari, Babak, Pordanjani, Parisa Moradi, Malekshahi, Ziba Veisi, Agi, Elnaz
- Database ID:
- RPEP-11091
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-11091APA
Gheydi, Mostafa; Bolhassani, Azam; Negahdari, Babak; Pordanjani, Parisa Moradi; Malekshahi, Ziba Veisi; Agi, Elnaz. (2025). From simulation to immunization: efficient non-viral delivery of HIV-1 Nefmut-Tat DNA construct using CM18-TAT11 cell penetrating peptide.. International journal of pharmaceutics, 686, 126334. https://doi.org/10.1016/j.ijpharm.2025.126334
MLA
Gheydi, Mostafa, et al. "From simulation to immunization: efficient non-viral delivery of HIV-1 Nefmut-Tat DNA construct using CM18-TAT11 cell penetrating peptide.." International journal of pharmaceutics, 2025. https://doi.org/10.1016/j.ijpharm.2025.126334
RethinkPeptides
RethinkPeptides Research Database. "From simulation to immunization: efficient non-viral deliver..." RPEP-11091. Retrieved from https://rethinkpeptides.com/research/gheydi-2025-from-simulation-to-immunization
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.